Equity · Healthcare
EDIT
NASDAQEditas Medicine (EDIT)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for EDIT to draw a line in its place.
- Market cap
- 420.8M USD
- Revenue, year to Dec 2025
- 40.5M USD
- EPS, diluted, year to Dec 2025
- −1.80 USD
- 52-week range
- 1.66 USD – 4.09 USD
- Avg volume
- 166.6K
as of Oct 7, 2026
Have Editas Medicine (EDIT) insiders bought or sold shares recently?
EDIT has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 5 November 2026.
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 03 Sep 2026 | Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER | Sell | 709 | 2K USD |
| 03 Sep 2026 | O'Neill Gilmore NeilCEO | Sell | 5,124 | 16K USD |
| 03 Sep 2026 | Parison AmySVP, Chief Financial Officer | Sell | 453 | 1K USD |
| 03 Aug 2026 | Parison AmySVP, Chief Financial Officer | Sell | 678 | 2K USD |
| 28 Jul 2026 | Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER | Sell | 4,928 | 13K USD |
| 03 Jun 2026 | Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER | Sell | 731 | 2K USD |
| 03 Jun 2026 | O'Neill Gilmore NeilCEO | Sell | 15,380 | 42K USD |
| 03 Jun 2026 | Parison AmySVP, Chief Financial Officer | Sell | 464 | 1K USD |
| 03 Mar 2026 | Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER | Sell | 749 | 2K USD |
| 03 Mar 2026 | Parison AmySVP, Chief Financial Officer | Sell | 474 | 957 USD |
| 03 Mar 2026 | O'Neill Gilmore NeilCEO | Sell | 5,394 | 11K USD |
| 03 Dec 2025 | Parison AmySVP, Chief Financial Officer | Sell | 461 | 993 USD |
| Sold | 14 open-market sales | 41,861 | $107K |
Showing the 12 most recent of 14 open-market trades in this window. The figures above count all of them.
2 other filings: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 05 Nov 2026 | Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER | Award | 16,533 | |
| 05 Nov 2026 | O'Neill Gilmore NeilCEO | Award | 43,567 |
Which funds hold Editas Medicine (EDIT)?
9 of the 45 institutional funds we track reported a Editas Medicine position for the quarter ended 30 Jun 2026 — a combined 33.0M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Renaissance Technologies | Trimmed | 2,468,919 | 8.0M USD | −37.8% |
| Marshall Wace | Added | 2,037,287 | 6.6M USD | +868.7% |
| D. E. Shaw & Co. | Held (±25%) | 1,901,002 | 6.2M USD | −2.2% |
| AQR Capital Management | Held (±25%) | 1,572,242 | 5.1M USD | +14.7% |
| Two Sigma Investments | Held (±25%) | 1,332,976 | 4.3M USD | −13.9% |
| Millennium Management | New position | 498,997 | 1.6M USD | |
| Citadel Advisors | Trimmed | 212,761 | 689K USD | −67.9% |
| Point72 Asset Management | Held (±25%) | 125,234 | 406K USD | +7.0% |
| Balyasny Asset Management | New position | 37,638 | 122K USD | |
| Man Group | Exited |
Have members of Congress traded Editas Medicine (EDIT)?
The most recent congressional trade disclosed in Editas Medicine is a sale by Daniel S. Goldman (house, NY), dated 10 Apr 2023.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 10 Apr 2023 | Daniel S. Goldmanhouse · Democrat–NY | Sale | 1K USD–15K USD | 39 days |
| 17 Nov 2020 | Donald S. Beyer, Jr.house · Democrat–VA | Purchase | 1K USD–15K USD | 14 days |
| 27 Apr 2020 | Donald S. Beyer, Jr.house · Democrat–VA | Sale | 1K USD–15K USD | 12 days |
| 09 Jan 2020 | Donald S. Beyer, Jr.house · Democrat–VA | Purchase | 1K USD–15K USD | 44 days |
| 23 Dec 2019 | Donald S. Beyer, Jr.house · Democrat–VA | Purchase | 1K USD–15K USD | 10 days |
| 22 Nov 2019 | Donald S. Beyer, Jr.house · Democrat–VA | Purchase | 1K USD–15K USD | 22 days |
What has been filed or recorded for Editas Medicine (EDIT)?
The filings we hold for Editas Medicine, newest first: 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Jun 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.15 USD | |
| 30 Jun 2026 | Financials | Total assets | 237.4M USD | at period end |
| 30 Jun 2026 | Financials | Total equity | 105.3M USD | at period end |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.26 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −1.80 USD | |
| 31 Dec 2025 | Financials | Revenue | 40.5M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −160.1M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −1.80 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.28 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.63 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.92 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −2.88 USD | |
| 30 Sep 2024 | Quarterly earnings | Q3 2024 reported | EPS −0.75 USD |
Editas Medicine (EDIT): frequently asked questions
What is Editas Medicine’s market cap?
Editas Medicine is worth 420.8M USD by market value as of 7 Oct 2026, which is the share price times the shares on issue from its SEC filings.
What is Editas Medicine’s revenue?
Editas Medicine reported revenue of 40.5M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Editas Medicine insiders bought or sold shares recently?
No Editas Medicine insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 5 Nov 2026 (SEC Form 4). See Insiders
Which funds own Editas Medicine?
9 of the 45 funds we track reported a Editas Medicine position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Renaissance Technologies, Marshall Wace and D. E. Shaw & Co. See Funds
Have members of Congress traded Editas Medicine?
Yes. 6 trades in Editas Medicine appear in the congressional disclosures we hold; the latest is a sale by Daniel S. Goldman (House, NY) dated 10 Apr 2023, filed 19 May 2023. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Editas Medicine last report earnings?
Editas Medicine last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −0.15 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- House disclosuresU.S. House of Representatives financial disclosures
- SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings